secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0001140361-23-050007
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

F351 Phase III enrollment completed ahead of schedule for HBV liver fibrosis
----------------------------------------------------------------------------

- Beijing Continent completed subject enrollment for F351 Phase III trial in China, more than two months ahead of initial expectation.
- Trial aims to confirm efficacy of F351 for liver fibrosis associated with chronic hepatitis B; safety comparable to Phase II.
- F351 received Breakthrough Therapy designation from NMPA in 2021; top-line data expected after 52-week data collection.
- BC, the trial sponsor, will become a subsidiary of Catalyst Biosciences per prior October 24 disclosure; no change to GNI consolidation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123050007/0001140361-23-050007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123050007/ny20009756x7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-050007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer